Biomolecular Characteristics of Reminder-Focused Positive-Psychiatry

Status Recruiting

Clinical Trial Summary

Objective: Posttraumatic stress disorder (PTSD) is a prevalent neuropsychiatric disorder in children and is associated with increased neurovascular inflammation, suicidality, adulthood mental health disorder, and major adverse events. Reminder focused positive psychiatry (RFPP) has been shown as well tolerated feasible trauma focused intervention that is associated with improved core PTSD symptoms, decreased severity of reactivity to PTSD trauma reminders, and increased vascular function. This study evaluates the clinical and biomolecular characteristics of RFPP in adolescents with PTSD. Research Design/Overall Impact: After obtaining parents' informed consent and adolescent's assent, 60 adolescents aged 11-15 years old with PTSD, and free of known medical and other major psychiatric disorders will be recruited from the pool of eligible adolescents at Olive View UCLA Pediatrics Clinics (>3000 adolescents with PTSD). Eligible adolescents will be randomized to 1) RFPP group intervention, or 2) an attentional control condition (group process). Thirty subjects in each group will receive twice weekly telehealth intervention of either RFPP or group process, for 6 weeks, and undergo 4 blinded neuropsychiatric assessments at baseline, 3, 6, and 24 weeks. Parents will receive weekly interventions of either positive psychoeducation or group process, for 6 weeks and undergo baseline, 3, 6- and 24-weeks neuropsychiatric assessment. Vascular function, inflammatory biomarkers including CRP, homocysteine, and stress involved gene expression biomarkers (i.e. changes in gene expression of FKBP5, DDX6, B2M, LAIR1, RTN4, NUB1, and a multi-gene Conserved Transcriptional Response to Adversity score (CTRA) will be measured at baseline and 6-week. The primary and secondary endpoints are a) changes in PTSD core and reactivity to trauma reminder severity score in response to RFPP intervention, b) changes in wellbeing, biopsychosocial trait, vascular function, neuroinflammation and gene expression biomarkers in response to RFPP, and c) changes in parents' wellbeing and biopsychosocial trait as well as child-parent interactions.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04529031
Study type	Interventional
Source	University of California, Los Angeles
Contact	Naser Ahmadi, MD PhD
Phone	424 298 8846
Email	ahmadi@ucla.edu
Status	Recruiting
Phase	N/A
Start date	May 1, 2022
Completion date	December 28, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03384706` - A Comparison of CPT Versus ART Versus WL	N/A
Completed	`NCT03418129` - Neuromodulatory Treatments for Pain Management in TBI	N/A
Completed	`NCT03129204` - Sensation Awareness Focused Training for Spouses	N/A
Recruiting	`NCT05651295` - A Precision Medicine Approach to Target Engagement for Emotion Regulation	N/A
Completed	`NCT05113277` - Development and Evaluation of a Tonic Immobility Focused Psychoeducational Intervention	N/A
Recruiting	`NCT05327504` - Written Exposure Therapy for Veterans With SUD and PTSD	N/A
Recruiting	`NCT05843695` - Enhancing Psychotherapy for Veterans and Service Members With PTSD and Anxiety	N/A
Active, not recruiting	`NCT05530642` - An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel	N/A
Completed	`NCT00644423` - Omega-3 Fatty Acids and Post Traumatic Stress Disorder (PTSD)	N/A
Completed	`NCT02989987` - NET for SGBV Survivors in Eastern DR Congo	N/A
Completed	`NCT02320799` - Randomized Controlled Trial of Interpersonal Psychotherapy for Depression and PTSD Among HIV+ Women in Kenya	N/A
Recruiting	`NCT02293291` - Thermal Clinic Treatment in Gulf War Illness	Phase 1/Phase 2
Completed	`NCT02242136` - Treatment of Posttraumatic Stress Disorder and Aggressive Behavior in Soldiers and Ex-combatants	N/A
Completed	`NCT01911585` - Efficacy of 60-minute Versus 90-minute Sessions in Treating PTSD Using Prolonged Exposure	N/A
Completed	`NCT02720497` - The Efficacy of 90-Minute Versus 60-Minute Sessions of Prolonged Exposure for PTSD	N/A
Terminated	`NCT01408641` - Topiramate for Alcohol Use in Posttraumatic Stress Disorder	N/A
Completed	`NCT01693978` - Contingency Outcomes in Prolonged Exposure	N/A
Completed	`NCT01469754` - Longitudinal Survey Analysis in Lymphoma Survivors	N/A
Completed	`NCT02362477` - Telemental Health and Cognitive Processing Therapy for Female Veterans With Military-related PTSD	Phase 3
Terminated	`NCT01239173` - Emotional Memory Reactivation in Posttraumatic Stress Disorder	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Biomolecular Characteristics of Reminder-Focused Positive-Psychiatry — RFPP

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms